TY - JOUR T1 - Clinical Trial of Radiotherapy After Intravenous Injection of Acridine Orange for Patients with Cancer JF - Anticancer Research JO - Anticancer Res SP - 481 LP - 489 VL - 38 IS - 1 AU - KATSUYUKI KUSUZAKI AU - TETSUO TAKAI AU - HITOSHI YOSHIMURA AU - KAZUYA INOUE AU - SHIGEO TAKAI AU - NICOLA BALDINI Y1 - 2018/01/01 UR - http://ar.iiarjournals.org/content/38/1/481.abstract N2 - Aim: We previously found that low-dose X-ray treatment after systemic administration of acridine orange (AO), which is known to have a low toxicity in animals, inhibited tumor growth in experimental studies using mouse osteosarcoma. In this pilot study, we planned to verify the toxicity of intravenous injection of low-dose AO in humans and investigate the anticancer effect of radiation after systemic AO administration (iAOR) for human cancer. Patients and Methods: Eight patients with terminal cancer were treated with iAOR. Results: None of the patients exhibited an adverse effect from AO injection. Three out of the five patients who received a full course of iAOR exhibited clinical or image-based responses, whereas two patients did not. Conclusion: The systemic administration of AO was confirmed not to be toxic in humans, and iAOR was suggested to be potentially effective against radioresistant cancer. ER -